Top Markets
Coin of the day
Mural Oncology plc Mural Oncology plc

Mural Oncology plc

MURA
Rangering i aksjer #27062
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and... Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Aksjekurs
$2.04
Sist synkronisert: 2025-12-09
Markedsverdi
$35.38M
Endring (1 dag)
0.00%
Endring (1 år)
-2.39%
Land
IE
Handel Mural Oncology plc (MURA)

Kategori

P/B-forhold for Mural Oncology plc (MURA)
P/B-forhold per 2026 TTM: 0
Ifølge Mural Oncology plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Mural Oncology plc fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH